1. Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients.
- Author
-
Feys S, Carvalho A, Clancy CJ, Gangneux JP, Hoenigl M, Lagrou K, Rijnders BJA, Seldeslachts L, Vanderbeke L, van de Veerdonk FL, Verweij PE, and Wauters J
- Subjects
- Humans, SARS-CoV-2, Pulmonary Aspergillosis complications, Pulmonary Aspergillosis drug therapy, Pulmonary Aspergillosis diagnosis, COVID-19 complications, Critical Illness, Influenza, Human complications, Antifungal Agents therapeutic use
- Abstract
Influenza-associated pulmonary aspergillosis (IAPA) and COVID-19-associated pulmonary aspergillosis (CAPA) are increasingly recognised as important complications in patients requiring intensive care for severe viral pneumonia. The diagnosis can typically be made in 10-20% of patients with severe influenza or COVID-19, but only when appropriate diagnostic tools are used. Bronchoalveolar lavage sampling for culture, galactomannan testing, and PCR forms the cornerstone of diagnosis, whereas visual examination of the tracheobronchial tract during bronchoscopy is required to detect invasive Aspergillus tracheobronchitis. Azoles are the first-choice antifungal drugs, with liposomal amphotericin B as an alternative in settings where azole resistance is prevalent. Despite antifungal therapy, IAPA and CAPA are associated with poor outcomes, with fatality rates often exceeding 50%. In this Review, we discuss the mechanistic and clinical aspects of IAPA and CAPA. Moreover, we identify crucial knowledge gaps and formulate directions for future research., Competing Interests: Declaration of interests SF received travel grants for conference attendance from Pfizer and Gilead and a speakers' fee from The Healthbook Company. AC received speakers' fees from Gilead. CJC reports research grants from Merck and Cidara; consulting fees or participation on advisory boards for Shionogi, Scynexis, and Venatorx; and lecture honoraria from Gilead. J-PG received consultancy and speaker fees from Gilead, Mundipharma, and Pfizer. MH received grants and research funding from Astellas, Gilead, MSD, Pfizer, Euroimmun, F2G, Pulmocide, AiCuris, Partners, IMMY, Melinta, Mundipharma, Shionogi, and Scynexis. KL received consultancy fees from MRM Health and Mundipharma; speakers' fees from Pfizer and Gilead; a service fee paid to the institution from Thermo Fisher Scientific and TECOmedical; and fees for advisory board participation from MSD and Pfizer. BJAR received research grants from Gilead; consulting fees from F2G; payment for lectures from Gilead; support for attending meetings from Pfizer, Gilead, and F2G; and reports participation on a data safety monitoring and advisory board for Exevir. LV received support for a public doctoral defence from Pfizer; and travel support from Gilead and Pfizer for conference attendance. PEV received research grants from F2G and Gilead; and speakers' fees from Mundipharma, F2G, Gilead, and Pfizer. JW received an institutional research fund from Pfizer; investigator-initiated grants from Pfizer, Gilead, and MSD; speakers' and travel fees from Pfizer, Gilead, and MSD; declares participation in advisory boards of Pfizer and Gilead; and declares receipt of study drugs from MSD. All other authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF